Loading...
By Kelly Young
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Valsartan/sacubitril and ivabradine are recommended for heart failure in updated guidelines from the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America.
Valsartan/sacubitril is an angiotensin receptor-neprilysin inhibitor (ARNI). By blocking that receptor, it inhibits the breakdown of bradykinin and in turn reduces blood volume. For heart failure with reduced ejection fraction, an ARNI, angiotensin II receptor blocker (ARB), or angiotensin-converting-enzyme (ACE) inhibitor is recommended, together with a beta blocker and aldosterone antagonist. An ARNI shouldn't be coadministered with an ACE inhibitor or in patients with an angioedema history. Since both drug classes affect bradykinin, they significantly increase angioedema risk.
Ivabradine, a sinoatrial node modulator, may help reduce hospitalizations in patients with symptomatic stable chronic heart failure with reduced ejection fraction who are taking a maximum tolerated dose of a beta blocker and whose resting heart rate is 70 beats per minute or greater.
Dr. Harlan Krumholz of NEJM Journal Watch Cardiology had this perspective: "This much anticipated guideline update interestingly shows restraint about two new therapies for heart failure, failing to give the new drugs, an ARNI and ivabradine, the same endorsement as ACE inhibitors and ARBs. For ARNI, some may promote the Class I recommendation, but the committee gave it a level of evidence below ACE inhibitors and ARBs, which gives people reason not to jump to the more expensive option. For ivabradine, the class of recommendation and strength of evidence are both lower."
Comment
LINK(S):
Circulation article (Free PDF)
Circulation editorial (Free PDF)
Background: NEJM Journal Watch Cardiology coverage of 2013 heart failure guidelines (Free)